Holmusk Gets Strategic Investment from Northwell, Optum Ventures and More to Build Evidence-Based Platform for Behavioral Health

Data science and health technology company Holmusk, which is building a large-scale evidenced-based platform for behavioral health, recently closed a strategic investment round.

Holmusk, whose last fundraising effort was a Series A round in May 2020, received investments from new participants including Novartis (dRx Capital) and Northwell Holdings.

Northwell Holdings is the investment arm of Northwell Health, which is the largest health care provider and private employer in New York state.


Holmusk also received funding from existing investors including Optum Ventures, Health Catalyst Capital and Heritas Capital. The total amount of funding raised by Holmusk in the round was not disclosed.

Prior to the round, Holmusk had raised $31.3 million, according to fundraising tracking site Crunchbase.

“Today’s news demonstrates industry validation of our Real-World Evidence strategy in behavioral health with the addition of leading pharma and provider players,” Nawal Roy, the founder and CEO of Holmusk, said in a press release.


Holmusk plans to use the money to expand its global operations and continue building what it says is the world’s largest evidence-based platform, which is fueled by behavioral health data and digital solutions.

Holmusk’s flagship product, NeuroBlu, currently has more than 20 years worth of data stored on more than a half a million patients, in excess of 20 million encounters.

“This strategic round marks an exciting milestone for Holmusk as we continue to reinvent the ways in which we care for patients with behavioral health needs,” Holmusk Board Chairman Michael Weintraub said in a press release.

Founded in 2015, Holmusk is headquartered in Singapore and New York. The company also has offices in a number of global locations including London and Shanghai, as well as a domestic office in Durham, North Carolina.

Companies featured in this article:

, , , , , ,